Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

100% ORR; 75% CR/sCR; and evidence of durable clinical benefit in a population with poor prognostic features observed in the dose escalation cohorts with CART-ddBCMA FOSTER CITY, Calif. , May 9, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell...

Click to view original post